Registered title, quoted from ClinicalTrials.gov
Sintilimab Plus Bevacizumab and SIRT for Intermediate-advanced HCC
An open trial on hepatocellular carcinoma, registered on ClinicalTrials.gov. Led by Second Affiliated Hospital of Guangzhou Medical University; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT06397222, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 6
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (6 points)Hide the checklist
18 years to 75 years; sex: all
Registered eligibility fields
Child-Pugh score 5-7
Inclusion criterion 4
Use of immunosuppressive medications within 4 weeks prior to the first dose of study treatment
Exclusion criterion 11
Major surgical procedure or unhealed wound, ulcer, or fracture within 4 weeks prior to the first dose of study treatment
Exclusion criterion 12
Any life-threatening bleeding event within the previous 3 months, including the need for blood transfusion, surgical or localized treatment, or ongoing drug therapy
Exclusion criterion 13
Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1
Inclusion criterion 5
Peripheral blood white blood cell count <3×10\^9/L and platelet count <50×10\^9/L
Exclusion criterion 14
Pregnant or lactating patients
Exclusion criterion 20
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; scans and measurable lesions; other conditions the trial excludes.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06397222, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Unresectable HCC (BCLC stage B/C or CNLC II/III) with diagnosis confirmed by histology/cytology or clinically
- At least one measurable untreated lesion
- Intrahepatic tumors can be treated with 1-2 sessions of SIRT
- Child-Pugh score 5-7
- Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1
- Life expectancy of at least 3 months
- Patients with active hepatitis B are allowed, but they need to receive antiviral treatment to achieve a HBV DNA<10\^3 IU/mL
- Patients with hepatitis C need to finish the anti-HCV treatment
Exclusion Criteria:
- tumor extent ≥70% liver occupation
- Tumor thrombus involving main portal vein or both the first left and right branches of portal vein
- Vena cava invasion
- Central nervous system metastasis
- Metastatic disease that involves major airways or blood vessels
- Patients who previously received hepatic arterial infusion chemotherapy (HAIC), transarterial chemoembolization (TACE), transarterial embolization (TAE), radiotherapy, systemic therapy for HCC
- History of organ and cell transplantation
- Prior esophageal and/or gastric varices bleeding
- Hepatic dysfunction, such as ascites, esophagogastric varices, hepatic encephalopathy
- Evidence of portal hypertension with high risk of bleeding
- Use of immunosuppressive medications within 4 weeks prior to the first dose of study treatment
- Major surgical procedure or unhealed wound, ulcer, or fracture within 4 weeks prior to the first dose of study treatment
- Any life-threatening bleeding event within the previous 3 months, including the need for blood transfusion, surgical or localized treatment, or ongoing drug therapy
- Peripheral blood white blood cell count <3×10\^9/L and platelet count <50×10\^9/L
- Prolonged prothrombin time >4 seconds
- Severe organ (heart, lung, kidney) dysfunction
- History of other malignancies
- Co-infection with hepatitis B and C viruses
- Human immunodeficiency virus infection
- Pregnant or lactating patients
Quoted from ClinicalTrials.gov, NCT06397222, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT06397222, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.